UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Buys 85,969 Shares of Personalis, Inc. $PSNL

Key Points

• UBS Asset Management increased its Personalis stake by 85,969 shares, or 7,822.5%, to 87,068 shares valued at approximately $1.17 million. Institutional investors collectively own 61.91% of PSNL.
• Personalis reported quarterly revenue of $22.36 million, exceeding estimates, but its loss of $0.30 per share was wider than expected. Analysts project a full-year loss of $1.07 per share.
• PSNL shares opened at $16.21, near their 52-week high of $18.89, while analyst sentiment remains mixed with a consensus rating of Hold and an average price target of $14.54; company insiders sold 256,233 shares last quarter.

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 7,822.5% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 87,068 shares of the company's stock after purchasing an additional 85,969 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.08% of Personalis worth $1,167,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PSNL. Merck & Co. Inc. bought a new position in Personalis in the 2nd quarter worth about $188,202,236. T. Rowe Price Investment Management Inc. increased its position in shares of Personalis by 273.9% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,780,290 shares of the company's stock valued at $85,812,000 after buying an additional 7,896,714 shares during the period. BlackRock Inc. purchased a new stake in shares of Personalis in the second quarter worth about $94,905,000. Bank of America Corp DE purchased a new stake in shares of Personalis in the second quarter worth about $24,395,000. Finally, AIGH Capital Management LLC bought a new position in shares of Personalis in the second quarter valued at approximately $22,981,000. 61.91% of the stock is currently owned by institutional investors.

Personalis Stock Performance

Personalis stock opened at $16.21 on Friday. Personalis, Inc. has a fifty-two week low of $4.95 and a fifty-two week high of $18.89. The stock has a market cap of $1.70 billion, a P/E ratio of -14.87 and a beta of 2.31. The firm's fifty day moving average price is $14.84 and its 200-day moving average price is $10.56.

Personalis (NASDAQ:PSNL - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.04). The company had revenue of $22.36 million during the quarter, compared to analysts' expectations of $16.69 million. Personalis had a negative return on equity of 46.47% and a negative net margin of 153.84%. On average, analysts predict that Personalis, Inc. will post -1.07 earnings per share for the current year.

Insider Transactions at Personalis

In other news, CEO Christopher Hall sold 100,000 shares of the stock in a transaction dated Thursday, July 9th. The stock was sold at an average price of $15.08, for a total transaction of $1,508,000.00. Following the transaction, the chief executive officer directly owned 235,986 shares in the company, valued at approximately $3,558,668.88. This represents a 29.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the firm's stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the transaction, the chief financial officer directly owned 198,833 shares in the company, valued at approximately $2,620,618.94. This represents a 20.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 256,233 shares of company stock valued at $3,568,236 over the last quarter. Company insiders own 4.20% of the company's stock.

Wall Street Analyst Weigh In

Several brokerages have commented on PSNL. Weiss Ratings reissued a "sell (d-)" rating on shares of Personalis in a report on Friday, July 17th. BTIG Research upped their price target on shares of Personalis from $11.00 to $16.25 and gave the stock a "buy" rating in a report on Monday, July 20th. Craig Hallum lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 price objective for the company. in a research note on Monday, August 24th. TD Cowen restated a "buy" rating on shares of Personalis in a research report on Wednesday, July 15th. Finally, Lake Street Capital lowered Personalis from a "buy" rating to a "hold" rating and set a $16.25 target price on the stock. in a research note on Monday, July 20th. Four analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $14.54.

Personalis Profile

Personalis, Inc is a genomics company focused on precision oncology and advanced molecular testing. The company develops and commercializes genomic products designed to help identify, monitor and characterize cancer, supporting more informed treatment decisions and the development of targeted therapies.

Its offerings include tissue- and blood-based tumor profiling, liquid biopsy testing and immune profiling. Personalis' technologies are designed to detect and track tumor-derived signals, evaluate genomic alterations and provide insights into the interaction between cancer and the immune system.

Want to see what other hedge funds are holding PSNL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Personalis, Inc. (NASDAQ:PSNL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.